Schrödinger

New York, New York, United States

Drug Discovery/Development Biotech PharmaTechIPO

Schrödinger is an international scientific software and biotechnology company, founded in 1990, developing computational tools for drug discovery and materials science. Its physics-based platform, integrating AI and machine learning, accelerates the discovery of high-quality molecules and is used by top biopharma companies globally.

Schrödinger hero image

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Schrödinger on @MedStartr Today Schrödinger is an international scientific software and biotechnology company, founded in 1990, developing computational tools for drug discovery and materials science. Its physics-based platform, integrating AI and machine learning, accelerates the discovery of high-quality molecules and is used by top biopharma companies globally. #BCellMalignancies #SOS1AndKRASDrivenTumors #ImmunologyAndInflammation #TYK2 #NLRP3Inhibitors #Neurology #ObesityOverweight #MetabolicDiseases #PulmonaryArterialHypertensionPAH #InflammatoryBowelDisease #NonSmallCellLungCancer #CancerOncology #DrugDiscoveryDevelopment #Biotech #PharmaTech #MedMo #MedStartrVentures

https://www.medstartr.ai/s/SqfYHZ_dH_4

Get Involved in Schrödinger

1 engagement

How We Help

Problem Statement

The company solves the problem of inefficient and lengthy traditional molecular discovery and design by transforming the process through a physics-based computational platform, aiming to accelerate the development of therapeutics and materials.

Core Technology

physics-based computational platform

Key Differentiators

accelerates drug discovery by enabling the rapid and accurate discovery of high-quality, novel molecules; reduces time and cost of bringing new drugs to market; works with all of the top 20 global biopharma companies

Clinical Focus

oncology programs

Target Customers

Global pharmaceutical companies (e.g., 19 of top 20), and collaboration partners for drug discovery.

Product Stage

Software platform is Mature/GA; Drug discovery programs are Concept/R&D (preclinical/clinical).

Company Info

Business Model: B2B (Software licensing) and a drug discovery model, advancing preclinical and clinical programs internally and through collaborations. SaaS is implied through platform licensing.
Founded: 1990
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.schrodinger.com/

Disease Areas

B-Cell Malignancies SOS1- and KRAS-driven Tumors Immunology and Inflammation TYK2 NLRP3 Inhibitors Neurology Obesity & Overweight Metabolic Diseases Pulmonary Arterial Hypertension (PAH)IBD Non-Small Cell Lung Cancer Cancer & Oncology

Technologies

Computational ToolsMachine LearningDrug DiscoveryMaterials ScienceSoftware & PlatformsPhysics-Based Computational PlatformMolecular DiscoveryMolecular DesignMolecular ModelingMaestroGlideFEP+PrimeLiveDesignDesmondAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

Their platform is used by 19 of the top 20 global pharmaceutical companies, validating its utility. The company is also actively advancing preclinical and clinical drug discovery programs.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Schrödinger?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.